Samantha Aguilar, PharmD, BCIDP, AAHIVP

🚨IV fosfo finally FDA approved in US for cUTI d/t E. coli or Kleb pneumo. -Cost? -Folks willing to use it for Kleb (or other Enterobacterales) in the absence of CLSI BPs? -Dose: 6G IV q8h…Tolerability in real-world? 🤔 Lots of questions to consider…. #IDTwitter #TwitteRx

Apply to our PGY1 Pharmacy Residency Program at Ochsner LSU Health Shreveport! 💊 Learn more about our program: lnkd.in/eftPgv36 💊 #PharmacyResidency #PGY1 #OchsnerLSUHealth #PhORCAS #ClinicalPharmacy #ASHP #PharmacyLeadership #ResidencyRecruitment

🔥2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Group A Streptococcal (GAS) Pharyngitis: Risk assessment using clinical scoring systems in children and adults🔥 #IDXposts idsociety.org/practice-guide…

Update Guidelines on Occupational HIV PEP 🔑Recommendations: -Start PEP ASAP and within 72hrs -Preferred: BIC/FTC/TAF or DTG/XTC/TXF, for 28 days -Final test at week 12 -Shared decision making (forgo PEP or stop early) if source has undetectable HIV RNA doi.org/10.1017/ice.20…

New and emerging drugs for the treatment of invasive fungal infections doi.org/10.1080/146565…

Do you still see and manage COVID-19 patients ?! 🆕🔥 IDSA Guidelines on the Treatment and Management of Patients with COVID-19 COVID-19 severity Approach in mild mod Bari Vs Toci #IDXposts idsociety.org/practice-guide…

@BradSpellberg @ABsteward 🤣🤣🤣

@ABsteward When you name a trial GAME CHANGER, it does set some pretty high expectations right up front. Next time, maybe try: MEH, or WE’LL SEE, or SHOULDER SHRUG EMOJI (a long name admittedly), or something like that?

🔥Just published The GAME CHANGER RCT Among patients with a hospital-acquired or health-care-associated Gram-negative bloodstream infection, cefiderocol resulted in non-inferior but not superior 14-day mortality compared with standard of care #IDXposts share.google/wnXjZuhBYFBOA3…

In the S. aureus methicillin-susceptible experimental #endocarditis model, daptomycin combinations with β-lactams had better activity than monotherapies in sterilizing valve vegetations. These findings support their use in clinical practice @hospitalclinic academic.oup.com/jid/article-ab…

How I manage patients with New Delhi metallo-beta-lactamase and OXA-48 producing Enterobacterales infections: a practical approach journals.lww.com/co-infectiousd…

🆕💫Establishing the Optimal Ceftriaxone MIC for Predicting ESBL Production in BSIs The study suggests the commonly used ceftriaxone MIC threshold of ≥2 μg/mL for ESBL detection lacks specificity; a cutoff of 8 µg/mL or higher may be more appropriate. academic.oup.com/ofid/article/d…

Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence ✅ Just Accepted 🔗 bit.ly/4m8inAG

Standardized Infliximab Regimen to Treat Severe Central Nervous System Tuberculosis: A Case Series of 18 Patients ✅ Just Accepted 🔗 doi.org/10.1093/ofid/o…

Main mechanisms of resistance to antifungals in Candida spp. doi.org/10.3390/pathog…

🆕💫 Review In vitro antimicrobial activity and clinical use of trimethoprim-sulfamethoxazole for infections due to KPC-producing Gram-negative pathogens #IDXposts link.springer.com/article/10.100…

@accpinfdprn I use 2g daily outside of UTI and SBP, but recognize the CLSI does use 1g to establish breakpoints. Beta lactams are so safe, I’ll even do 2gq12 in patients with BMI >30 (+the traditional indications)

The ongoing battle of ceftriaxone 1g vs 2g, which team are you on 🤺👊?! Another retrospective study showing 2g may result in better outcomes in critically ill inpatients with CAP! Check it out 💥🧫💊 #IDXposts academic.oup.com/jac/article/80…

Commensal oral bacteria and their role in systemic diseases. doi.org/10.3390/antibi…

🆕🔥Prospective,multinational PK study by 🌟 @jasonroberts_pk Meropenem & pip/tazo optimised dosing regimens for critically ill patients receiving RRT Dosing nomograms developed to inform dosing for different RRT settings, urine outputs & target conc link.springer.com/article/10.100…

Dalbavancin exhibits poor activity against E. faecalis, and impairs the activity of β-lactams, especially amoxicillin. Dalbavancin should be used with caution in the treatment of E. faecalis infective endocarditis